Corporate Briefing Session 2024



Quran Recitation





Our Story



Business Overview



Key Financials



Question and Answers



Our Story

In pursuant of the demerger of the consumer healthcare business from GlaxoSmithKline plc, UK on July 18, 2022, to Haleon plc. an independent listed Company (listed on London Stock Exchange and New York Stock Exchange), the ultimate parent Company has changed from GlaxoSmithKline plc to **Haleon plc**. On 6th January 2023, the name of Company also changed to **Haleon Pakistan Limited (HALEON)** at SECP and PSX respectively.

Our People

HALEON For Health. With Humanity.





Our mission

Registered Office: 11 A, 11th Floor Sky Tower (East Wing),
Dolmen City, HC-3, Block 4, Scheme-5,
Clifton, Karachi, Pakistan
Karachi, Lahore, Multan and Islamabad
Jamshoro -State of the art facility for
manufacturing & packaging.

Total employees: 476 (HO: 159, Site: 317)

Diversity: 21% females, 79% males

Corporate Information

Board of Directors

Mr. M. Z. Moin Mohajir (Chairperson) Mr. Farhan Muhammad Haroon Syed Anwar Mahmood

Mr. Dilawar Meghani

Ms. Sumru Atalay Besceli

Mr. Oussama Abbas

Ms Ayesha Aziz

Board Audit Committee

Supply Chain Executive Committee

Human Resource, **Remuneration & Nomination Committee**

Mr. M. Z. Moin Mohajir

Mr. Oussama Abbas

(Chairperson)

Mr. Farhan Haroon

Syed Anwar Mahmood

(Chairperson)

Mr. M. Z. Moin Mohajir

Ms Ayesha Aziz (Chairperson) Syed Anwar Mahmood

Secretary: Marrium Ahmed

Mr. Dilawar Meghani

Secretary: Mohsin Mazher

Ms. Ayesha Aziz

Secretary: Ensherah Khan

Management Committee	
Mr. Farhan Muhammad Haroon	Chief Executive Officer
Mr. Dilawar Meghani	Chief Financial Officer
Ms. Mashal Mohammad	Legal Director and Company Secretary
Ms. Marrium Ahmed	Compliance and Internal Audit Lead
Mr. Ameer Taimur Zaid	Pakistan E2E SC and Jamshoro Site Lead
Ms. Sadaf Malik	Corporate Affairs Manager, MEA
Mr. Salman Altaf	Marketing Director
Syed Abrar Ali	Sales Director
Mr. Faisal Rafiq	Head of Expert
Mr. Mazhar Shams	Head of Regulatory
Mr. Khurram Haleem Khan	NRM Lead
Ms. Ensherah Khan	HR Business Partner

Company Secretary

Mashal Mohammad

Bankers

Chief Financial Officer

Dilawar Meghani

Chief Internal Auditor

Marrium Ahmed

Legal Advisors

Haroon Dugal Law Chambers

Auditors

KPMG Taseer Hadi & Co

- Standard Chartered
- **MCB**

Habib Metro

Risk Management Committee not formed since CRF in place (Compliance Risk Forum), held every quarter.



Our Story



Business Overview



Key Financials



Question and Answers



Expanding portfolio through organic and inorganic growth model

GSK Consumer Healthcare

Brands become part of Haleon as a result of demerger of consumer healthcare business from GSK Pakistan Limited in 2015.



Hvdrozole

parodontax









Brands become part of Haleon as a result of demerger of consumer healthcare business from Novartis Pharma (Pakistan) Limited merged in 2018











Pfizer

Brands become part of Haleon as a result of demerger of consumer healthcare business from Pfizer in 2018.











Brands Portfolio

FMCG

Oral Care





OVER THE COUNTER

Nutrition & Digestive

Skin Health

Respiratory

Pain Relief





















Recent Key Launches

Pain





Panadol Ultra

I




Sensodyne Kids




Senso Access


Revenue & EPS growth





Portfolio wise Sales – YTD September


Maintaining the upward trend by doing what matter most!











Key Brands Performance

Top 3 Brands contribute 80% to Total turnover







Responsible Business

Sustainability



Inaugration of Solar power Generation Project



Composting site in Jamshoro

Community Welfare



HALEON x UNICEF "Mothers Matter"



Haleon X TCF Supporting a school in Matiari, Sindh

Corporate Volunteering



Dar Ul Sukoon "Haleon Helps"

Awards and Achievements



The Pakistan Pharmaceutical Manufacturing Association (PPMA) declared Haleon amongst TOP 10 Pharmaceutical exporters of Pakistan.



13th Annual Corporate Social Responsibility Award Winner 2024



Guinness Book of World Records for "Largest Attendance for a pharmaceutical conference in one day"



Bronze Effie Award for CAC-1000 and Silver Effie Award for Sensodyne.



Haleon Limited secured **2nd Position** for Best Corporate Report in the Pharmaceutical Industry 2023.



Our Story



Business Overview



Key Financials



Question and Answers



Key Financial Highlights

Nine months ended 2024 results

PKR 27.5^{Bn}

PKR 9.2^{Bn}

PKR 5.4^{Bn}

Revenue

Gross Profit

Profit before tax

Revenue:

Growth of 16% vs SPLY – Higher by PKR 3.8bn.

Gross Profit:

Gross margin at 33.3%, +14.5% (PKR 4.7bn) vs SPLY.

OPEX:

PKR 3.6bn, +18.7% vs SPLY. Selling & Marketing and Administrative expenses increased by 16.6%.

Profit before tax:

Growth of 338% (PKR 4.2bn) vs SPLY. Profit before tax is 19.8% of sales which is + 14.6% vs SPLY.

HALEON

PKR 27.4

Earning per share

PKR 11.4

Q3 Earning per share



